Literature DB >> 35421076

COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022.

Dallas J Smith, Avi J Hakim, Gabriel M Leung, Wenbo Xu, W William Schluter, Ryan T Novak, Barbara Marston, Bradley S Hersh.   

Abstract

On January 6, 2022, a cluster of COVID-19 cases* caused by the Omicron variant of SARS-CoV-2, the virus that causes COVID-19, was detected in Hong Kong Special Administrative Region, China (Hong Kong), resulting in the territory's fifth wave of COVID-19 cases (1). This wave peaked on March 4, 2022, with 8,764 COVID-19 cases per million population (2), resulting in a total of 1,049,959 cases and 5,906 COVID-19-associated deaths reported to the Hong Kong Department of Health during January 6-March 21, 2022.† Throughout this period, the COVID-19 mortality rate in Hong Kong (37.7 per million population) was among the highest reported worldwide since the COVID-19 pandemic began (3). Publicly available data on age-specific vaccination coverage in Hong Kong with a 2-dose primary vaccination series (with either Sinovac-CoronaVac [Sinovac], an inactivated COVID-19 viral vaccine, recommended for persons aged ≥3 years or BNT162b2 [Pfizer-BioNTech], an mRNA vaccine, for persons aged ≥5 years), as of December 23, 2021,§,¶ and COVID-19 mortality during January 6-March 21, 2022, were analyzed. By December 23, 2021, 67% of vaccine-eligible persons in Hong Kong had received ≥1 dose of a COVID-19 vaccine, 64% had received ≥2 doses, and 5% had received a booster dose. Among persons aged ≥60 years, these proportions were 52%, 49%, and 7%, respectively. Among those aged ≥60 years, vaccination coverage declined with age: 48% of persons aged 70-79 years had received ≥1 dose, 45% received ≥2 doses, and 7% had received a booster, and among those aged ≥80 years, 20%, 18%, and 2% had received ≥1 dose, ≥2 doses, and a booster dose, respectively. Among 5,906 COVID-19 deaths reported, 5,655 (96%) occurred in persons aged ≥60 years**; among these decedents, 3,970 (70%) were unvaccinated, 18% (1,023) had received 1 vaccine dose, and 12% (662) had received ≥2 doses. The overall rates of COVID-19-associated mortality among persons aged ≥60 years who were unvaccinated, who had received 1 COVID-19 vaccine dose, and who had received ≥2 vaccine doses were 10,076, 1,099, and 473 per million population, respectively; the risk for COVID-19-associated death among unvaccinated persons was 21.3 times that among recipients of 2-3 doses in this age group. The high overall mortality rate during the ongoing 2022 Hong Kong Omicron COVID-19 outbreak is being driven by deaths among unvaccinated persons aged ≥60 years. Efforts to identify and address gaps in age-specific vaccination coverage can help prevent high mortality from COVID-19, especially among persons aged ≥60 years.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35421076      PMCID: PMC9020860          DOI: 10.15585/mmwr.mm7115e1

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   35.301


On January 6, 2022, a cluster of COVID-19 cases* caused by the Omicron variant of SARS-CoV-2, the virus that causes COVID-19, was detected in Hong Kong Special Administrative Region, China (Hong Kong), resulting in the territory’s fifth wave of COVID-19 cases (). This wave peaked on March 4, 2022, with 8,764 COVID-19 cases per million population (), resulting in a total of 1,049,959 cases and 5,906 COVID-19–associated deaths reported to the Hong Kong Department of Health during January 6–March 21, 2022. Throughout this period, the COVID-19 mortality rate in Hong Kong (37.7 per million population) was among the highest reported worldwide since the COVID-19 pandemic began (). Publicly available data on age-specific vaccination coverage in Hong Kong with a 2-dose primary vaccination series (with either Sinovac-CoronaVac [Sinovac], an inactivated COVID-19 viral vaccine, recommended for persons aged ≥3 years or BNT162b2 [Pfizer-BioNTech], an mRNA vaccine, for persons aged ≥5 years), as of December 23, 2021,, and COVID-19 mortality during January 6–March 21, 2022, were analyzed. By December 23, 2021, 67% of vaccine-eligible persons in Hong Kong had received ≥1 dose of a COVID-19 vaccine, 64% had received ≥2 doses, and 5% had received a booster dose. Among persons aged ≥60 years, these proportions were 52%, 49%, and 7%, respectively. Among those aged ≥60 years, vaccination coverage declined with age: 48% of persons aged 70–79 years had received ≥1 dose, 45% received ≥2 doses, and 7% had received a booster, and among those aged ≥80 years, 20%, 18%, and 2% had received ≥1 dose, ≥2 doses, and a booster dose, respectively. Among 5,906 COVID-19 deaths reported, 5,655 (96%) occurred in persons aged ≥60 years**; among these decedents, 3,970 (70%) were unvaccinated, 18% (1,023) had received 1 vaccine dose, and 12% (662) had received ≥2 doses. The overall rates of COVID-19–associated mortality among persons aged ≥60 years who were unvaccinated, who had received 1 COVID-19 vaccine dose, and who had received ≥2 vaccine doses were 10,076, 1,099, and 473 per million population, respectively; the risk for COVID-19–associated death among unvaccinated persons was 21.3 times that among recipients of 2–3 doses in this age group. The high overall mortality rate during the ongoing 2022 Hong Kong Omicron COVID-19 outbreak is being driven by deaths among unvaccinated persons aged ≥60 years. Efforts to identify and address gaps in age-specific vaccination coverage can help prevent high mortality from COVID-19, especially among persons aged ≥60 years. The Chinese Center for Disease Control and Prevention and the U.S. CDC conducted a descriptive analysis of COVID-19 incidence, mortality, age-specific vaccination coverage, and booster dose coverage after introduction of the Omicron variant in Hong Kong. Relative risks were calculated using mortality rates (deaths per million persons) by vaccination status and age, with the referent groups being ≥2-dose recipients; persons aged <30 years; or, within specific age groups, receipt of ≥2 vaccine doses. Data were obtained from publicly available sources, primarily the Hong Kong Department of Health () and Our World in Data (). This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. During February 2020–December 2021, Hong Kong reported 12,649 COVID-19 cases and 213 associated deaths. On January 6, 2022, the first cluster of COVID-19 cases attributable to the Omicron variant were identified in guests in a hotel for compulsory quarantine after arrival in Hong Kong from abroad (). Daily COVID-19 incidence increased sharply, from 1.7 per million population on January 6 to a peak of 8,764.2 per million on March 4, before declining to 2,716.0 by March 21, 2022. By February 14, 2022, 100% of sequenced isolates were Omicron variant, BA.2 lineage. As of December 23, 2021, two thirds (67%) of vaccine-eligible persons overall in Hong Kong had received ≥1 COVID-19 vaccine dose, 64% had received ≥2 doses, and 5% had received a booster dose (Table 1). Vaccination coverage varied by age; among persons aged 30–59 years, 82%, 80%, and 5% had received ≥1 dose, ≥2 doses, and a booster dose, respectively. Among persons aged ≥60 years, approximately one half (52% and 49%) had received ≥1 and ≥2 vaccine doses, respectively, and 7% had received a booster dose. Coverage declined with increasing age: 48% of persons aged 70–79 years and 20% of those aged ≥80 years had received ≥1 vaccine dose, 45% and 18% had received ≥2 doses, and 7% and 2% had received a booster dose.
TABLE 1

COVID-19 vaccination coverage, by age group — Hong Kong Special Administrative Region, China, December 23, 2021

Age group, yrsNo. of doses received/vaccination coverage*
≥1 dose
no./total no. (%)≥2 doses
no./total no. (%)Booster
no./total no. (%)
3–29
980,945/1,784,800 (55)
869,096/1,784,800 (49)
14,471/1,784,800 (0.8)
3–19
345,393/976,100 (35)
255,510/976,100 (26)
730/976,100 (0.1)
20–29
635,552/808,700 (79)
613,586/808,700 (76)
13,741/808,700 (2.0)
30–59
2,817,846/3,443,000 (82)
2,751,916/3,443,000 (80)
171,899/3,443,000 (5.0)
30–39
889,354/1,126,300 (79)
864,294/1,126,300 (77)
32,943/1,126,300 (3.0)
40–49
983,239/1,142,500 (86)
963,035/1,142,500 (84)
63,356/1,142,500 (6.0)
50–59
945,253/1,174,200 (81)
924,587/1,174,200 (79)
75,600/1,174,200 (6.0)
≥60
1,049,110/2,034,100 (52)
1,004,606/2,034,100 (49)
145,989/2,034,100 (7.0)
60–69
701,148/1,071,800 (65)
679,592/1,071,800 (63)
96,451/1,071,800 (9.0)
70–79
266,706/560,500 (48)
253,378/560,500 (45)
39,761/560,500 (7.0)
≥80
81,256/401,800 (20)
71,635/401,800 (18)
9,777/401,800 (2.0)
Total 4,847,901/7,261,900 (67) 4,625,618/7,261,900 (64) 332,359/7,261,900 (5.0)

Source: COVID-19 Vaccination Programme. https://www.covidvaccine.gov.hk

* Total persons vaccinated divided by total population in the age group.

† In Hong Kong, booster doses are considered third and fourth doses after the 2-dose primary COVID-19 vaccination series vaccines.

Source: COVID-19 Vaccination Programme. https://www.covidvaccine.gov.hk * Total persons vaccinated divided by total population in the age group. † In Hong Kong, booster doses are considered third and fourth doses after the 2-dose primary COVID-19 vaccination series vaccines. A total of 5,906 COVID-19–related deaths were reported in Hong Kong during January 6–March 21, 2022 (Table 2). The daily mortality rate increased from zero on January 6 to 34.8 per million on March 21 and peaked at 37.7 on March 14. Among all deaths, 4,118 (70%) occurred in unvaccinated persons and 5,655 (96%) occurred in persons aged ≥60 years. Unvaccinated decedents aged ≥60 years (3,970) accounted for 67% of total deaths, and among the 5,655 deaths in persons aged ≥60 years, 70% were in unvaccinated persons. Unvaccinated decedents aged ≥70 years (3,661) and ≥80 years (3,036) accounted for 62% and 51% of all deaths, respectively.
TABLE 2

COVID-19–associated mortality,* by age group and vaccination status — Hong Kong Special Administrative Region, China, January 6–March 21, 2022

Age group, yrs
Total no. of deaths
(% of total)
Age-specific mortality*
No. of deaths, by no. of vaccine doses
Mortality,* by no. of vaccine doses
None
1
≥2
None
1
≥2
Total
5,906 (100)
799
4,118
1,068
720
4,277
317
129
<30
21 (0.4)
11
13
4
4
29
6
4
<3
1 (0.0)
8
1
0
0
8
0
0
3–11
5 (0.1)
9
3
2
0
13
8
0
12–19
5 (0.1)
11
3
1
1
158
7
3
20–29
10 (0.2)
12
6
1
3
92
4
4
30–59
228 (4.0)
66
133
41
54
1,039
23
17
30–39
15 (0.3)
13
8
3
4
140
6
4
40–49
43 (0.7)
38
30
4
9
1,000
6
8
50–59
170 (2.9)
145
95
34
41
2,317
52
39
≥60
5,655 (95.9)
2,780
3,970
1,023
662
10,076
1,099
473
60–69
496 (8.4)
463
309
94
93
2,784
168
108
70–79
977 (16.5)
1,743
625
201
151
5,841
786
396
≥70
5,159 (87.4)
5,363
3,661
929
569
12,936
2,490
1,061
≥804,182 (70.8)10,4083,03672841817,2506,2072,696

* Deaths per million population.

† Age was unknown for two unvaccinated decedents.

* Deaths per million population. † Age was unknown for two unvaccinated decedents. Overall, the relative risk of dying from COVID-19 among unvaccinated persons in Hong Kong was 33.2 times the risk among persons who received ≥2 doses (Table 3). Compared with persons aged <30 years, mortality risk among those aged ≥60 years was 252.7 times as high, and among persons aged ≥80 years was 946.2 times as high. Among persons aged ≥60 years, the relative risks for death among those who were unvaccinated were 21.3 times the risk among persons who had received ≥2 doses and 2.3 times the risk among those who had received 1 vaccine dose.
TABLE 3

COVID-19 mortality* and relative mortality risk among persons aged <30 years, 30–59 years, and ≥60 years, overall and by age and vaccination status — Hong Kong Special Administrative Region, China, January 6–March 21, 2022

CharacteristicMortality rate*Relative mortality risk
Overall no. of COVID-19 vaccine doses received
≥2
129
Ref
1
317
2.5
0
4,277
33.2
All vaccination groups, by age group, yrs
<30
11
Ref
30–59
66
6
≥60
2,780
252.7
60–69
463
42.1
70–79
1,743
158.5
≥80
10,408
946.2
No. of doses received, by age group, yrs
<30
≥2
4
Ref
1
6
1.5
0
29
7.3
30–59
≥2
17
Ref
1
23
1.4
0
1,039
61.1
≥60
≥2
473
Ref
1
1,099
2.3
0
10,076
21.3
60–69
≥2
108
Ref
1
168
1.6
0
2,784
25.8
70–79
≥2
396
Ref
1
786
2.0
0
5,841
14.7
≥80
≥2
2,696
Ref
1
6,207
2.3
017,2506.4

Abbreviation: Ref = referent group.

* Deaths per million population.

† Compared with referent group of ≥2 doses.

Abbreviation: Ref = referent group. * Deaths per million population. † Compared with referent group of ≥2 doses.

Discussion

After the emergence of the Omicron variant in Hong Kong in early January 2022, COVID-19 cases increased rapidly, resulting in 5,906 deaths as of March 21, 2022. At the start of this outbreak, immunity in Hong Kong was presumed to be predominantly vaccine-derived as a result of a dynamic COVID-Zero strategy, whereby after successful containment, every case is investigated, and measures are implemented to interrupt onward transmission (). Although overall 2-dose vaccination coverage was 64%, rates varied between age groups and were lower among older adults: 2-dose vaccination coverage was 63% among persons aged 60–69 years, 45% among those aged 70–79 years, and 18% among those aged ≥80 years. New Zealand, a country with a much lower population density than Hong Kong, also had largely vaccine-derived immunity. Although New Zealand’s 2-dose COVID-19 vaccination coverage was 95% among persons aged ≥60 years, the country experienced a similar increase in incidence after introduction of Omicron; however, mortality in New Zealand peaked at 2.1 per million population per day compared with 38.0 in Hong Kong (). These findings align with data from existing studies indicating that the risk for death from COVID-19 increases with age and reinforce the effectiveness of vaccination in preventing death from the Omicron variant in older adults (,). COVID-19 vaccine-induced immunity wanes over time, but booster vaccinations can elicit a strong immune response and restore vaccine effectiveness (). At the beginning of the Omicron wave in Hong Kong, only 7% of persons aged ≥60 years had received a booster dose, including just 2% of those aged ≥80 years. The primary series of COVID-19 vaccines plus a booster dose is more effective at preventing severe outcomes caused by the Omicron variant than a primary series alone (). In addition to the low vaccination coverage among persons aged ≥60 years, waning immunity since the last vaccine dose could have contributed to COVID-19–associated mortality in Hong Kong. The reasons for low COVID-19 vaccination coverage among older persons in Hong Kong are not clear. Low vaccine confidence has presented major hurdles for governments aiming to reduce COVID-19 transmission and mortality. A June 2021 survey in Hong Kong found that 56.8% of participants were hesitant about or resistant to receiving a COVID-19 vaccine (). The dynamic COVID-Zero strategy, successful until the emergence of the Omicron variant, might have resulted in further complacency, particularly among older persons. A survey conducted during November 2020–January 2021 in China found that older adults were more likely to accept a COVID-19 vaccine if they perceived themselves to be at high risk for infection or had trust in the government (). Experience with the COVID-19 pandemic can motivate public health officials to increase vaccine distribution and coverage. Hong Kong targeted older persons for vaccination during the outbreak. As of March 21, 2022, 2-dose COVID-19 vaccination coverage in Hong Kong has increased substantially, to 81% among persons aged 60–69 years, 69% among persons aged 70–79 years, and 39% among persons aged ≥80 years (). The findings in this report are subject to at least four limitations. First, summary-level data were analyzed, and other risk factors for death, including comorbidities, could not be examined. Second, completeness of reporting of COVID-19–attributed deaths is unknown. Third, immunity due to previous infection could not be assessed; however, such immunity was likely low given that few cases had been reported during previous waves (). Finally, vaccine effectiveness can vary by type and timing of vaccination, which were not accounted for in this analysis. During January–March 2022, data from Hong Kong suggested that higher mortality rates were driven by low vaccination coverage among older adults. These data underscore the importance of monitoring age-specific vaccination coverage and implementing strategies that increase COVID-19 vaccination coverage among all population groups, especially those most at risk for severe illness. Efforts to identify disparities in age-specific vaccination rates and address gaps in vaccination coverage among groups at high risk can help prevent high mortality from COVID-19, especially in older adults.

What is already known about this topic?

COVID-19 vaccines are important tools to protect populations from severe disease and death.

What is added by this report?

Among persons aged ≥60 years in Hong Kong, 49% had received ≥2 doses of a COVID-19 vaccine, and vaccination coverage declined with age. During January–March 2022, reported COVID-19–associated deaths rose rapidly in Hong Kong. Among these deaths, 96% occurred in persons aged ≥60 years; within this age group, the risk for death was 20 times lower among those who were fully vaccinated compared with those who were unvaccinated.

What are the implications for public health practice?

Efforts to identify and address gaps in age-specific vaccination coverage can help prevent high mortality from COVID-19, especially in older adults.
  3 in total

1.  Willingness to accept COVID-19 vaccine among the elderly and the chronic disease population in China.

Authors:  Jiahao Wang; Beibei Yuan; Xinran Lu; Xiaoxue Liu; Li Li; Shufan Geng; Haijun Zhang; Xiaozhen Lai; Yun Lyu; Huangyufei Feng; Rize Jing; Jia Guo; Yingzhe Huang; Xun Liang; Wenzhou Yu; Hai Fang
Journal:  Hum Vaccin Immunother       Date:  2021-12-14       Impact factor: 3.452

2.  Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China.

Authors:  Joseph T Wu; Kathy Leung; Mary Bushman; Nishant Kishore; Rene Niehus; Pablo M de Salazar; Benjamin J Cowling; Marc Lipsitch; Gabriel M Leung
Journal:  Nat Med       Date:  2020-03-19       Impact factor: 53.440

  3 in total
  22 in total

1.  Preliminary Study of the Protectiveness of Vaccination Against the COVID-19 in the Outbreak of VOC Omicron BA.2 - Jilin City, Jilin Province, China, March 3-April 12, 2022.

Authors:  Xuebin Fan; Shan Lu; Lu Bai; Haican Liu; Junshao Fu; Xiaoxun Jin; Yulong He; Jinxing Lu; Xiaoping Dong
Journal:  China CDC Wkly       Date:  2022-05-06

2.  Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California.

Authors:  Joseph A Lewnard; Vennis X Hong; Manish M Patel; Rebecca Kahn; Marc Lipsitch; Sara Y Tartof
Journal:  Nat Med       Date:  2022-06-08       Impact factor: 87.241

3.  Factors affecting the serologic response to SARS-CoV-2 vaccination in patients with solid tumors: A prospective study.

Authors:  Atike Pınar Erdoğan; Ferhat Ekinci; Sinem Akçalı; Gamze Göksel
Journal:  J Infect Chemother       Date:  2022-06-06       Impact factor: 2.065

4.  Persevere in the Dynamic COVID-Zero Strategy in China to Gain a Precious Time Window for the Future.

Authors:  Jue Liu; Min Liu; Wannian Liang
Journal:  China CDC Wkly       Date:  2022-05-06

5.  Determinant Factors of COVID-19 Vaccine Hesitancy Among Adult and Elderly Population in Central Java, Indonesia.

Authors:  Aras Utami; Ani Margawati; Dodik Pramono; Arwinda Nugraheni; Setyo Gundi Pramudo
Journal:  Patient Prefer Adherence       Date:  2022-06-28       Impact factor: 2.314

6.  Clinical and Pulmonary CT Characteristics of Patients Infected With the SARS-CoV-2 Omicron Variant Compared With Those of Patients Infected With the Alpha Viral Strain.

Authors:  Naibin Yang; Chuwen Wang; Jiajia Huang; Jing Dong; Jihui Ye; Yuan Fu; Jingfeng Huang; Daojie Xu; Gang Cao; Guoqing Qian
Journal:  Front Public Health       Date:  2022-07-12

7.  Vaccine Resistance and Hesitancy among Older Adults Who Live Alone or Only with an Older Partner in Community in the Early Stage of the Fifth Wave of COVID-19 in Hong Kong.

Authors:  Dexing Zhang; Weiju Zhou; Paul Kwok-Ming Poon; Kin On Kwok; Tracy Wai-Sze Chui; Phoebe Hoi Yi Hung; Bonny Yin Tung Ting; Dicken Cheong-Chun Chan; Samuel Yeung-Shan Wong
Journal:  Vaccines (Basel)       Date:  2022-07-13

8.  Outbreak control management: Lessons from SARS-CoV-2 infections in 2020-2022 in Hong Kong, an international municipality with high-frequency travelers.

Authors:  Yaxiu Feng; Ching Han Young; Siu Hin Lau; Ming-Liang He
Journal:  MedComm (2020)       Date:  2022-07-25

9.  The Association between Risk Perception and Hesitancy toward the Booster Dose of COVID-19 Vaccine among People Aged 60 Years and Older in China.

Authors:  Chenyuan Qin; Wenxin Yan; Liyuan Tao; Min Liu; Jue Liu
Journal:  Vaccines (Basel)       Date:  2022-07-12

10.  Assessment of SARS-CoV-2-Infected Patients and Their Clinical Outcomes During the Third Wave in India: A Single-Center Observational Study.

Authors:  Praveen R Shahapur; Roopa Shahapur; Venkataramana Kandi; Tarun Kumar Suvvari; Sabitha Vadakedath
Journal:  Cureus       Date:  2022-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.